April 24, 2020 / 1:34 AM / a month ago

BRIEF-Innovent And Eli Lilly Announce NMPA Acceptance Of Supplemental New Drug Application For Sintilimab

April 23 (Reuters) - Innovent Biologics Inc:

* INNOVENT AND ELI LILLY ANNOUNCE NMPA ACCEPTANCE OF A SUPPLEMENTAL NEW DRUG APPLICATION FOR SINTILIMAB IN COMBINATION WITH ALIMTA® (PEMETREXED) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below